Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition. Notably, this patent was issued following an accelerated review procedure which enables innovators to receive a final decision within 12 months of application. The issued patent is a major milestone for Tethys and has potential applicability to other Tethys products in development.
“The rapid issuance of this first PreDx patent reflects the company's commitment to an intellectual property portfolio that will support its rapid commercialization of novel technology to identify patients at risk of developing type 2 diabetes and other chronic cardiometabolic diseases”
PreDx DRS is a simple-to-use, multimarker blood test that enables accurate identification of patients who have the highest risk of developing type 2 diabetes within five years. Of the more than 57 million Americans who are categorized as being at high risk for diabetes based on conventional testing, most will never develop diabetes. PreDx DRS facilitates identification of the 10-20 percent of individuals at the highest, near-term risk, for whom lifestyle or other intervention may be most beneficial.